未登录

S

Stuart Carroll

University of Canberra

H指数:18

被引数:965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling Study

mRNA-1345基呼吸合胞病毒疫苗在扩展接种运动下于英国老年人中的潜在公共卫生影响：一项建模研究

Vaccines 2025, Vol. 13, Page 1065

IF0

2025-10-180

OAAI

How much physical activity and sitting should women with heart disease do to reduce their risk of death?: :a cohort mortality survival tree analysis

心脏病女性应进行多少身体活动和静坐才能降低死亡风险？：一项队列死亡率生存树分析

EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING

IF3.9

2025-07-010

OAAI

New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement

IF3.4

2024-02-240

OAAI

Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines

IF3.4

2022-08-1512

OAAI

Making prevention a reality: living health and wellbeing at Sanofi

PERSPECTIVES IN PUBLIC HEALTH

IF2.6

2020-12-280

OAAI

Quantifying the direct secondary health care cost of seasonal influenza in England

BMC PUBLIC HEALTH

IF3.6

2020-09-2919

OAAI

COST-EFFECTIVENESS OF VACCINATION STRATEGIES TO PREVENT INFECTIOUS DISEASES: A SYSTEMATIC LITERATURE REVIEW

VALUE IN HEALTH

IF6

2018-10-011

OAAI

AN ECONOMIC MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

VALUE IN HEALTH

IF6

2018-10-013

OAAI

A DYNAMIC TRANSMISSION MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

VALUE IN HEALTH

IF6

2018-10-013

OAAI

BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOM

VALUE IN HEALTH

IF6

2018-10-010

OAAI

UK EPIDEMIOLOGY AND CLINICAL BURDEN OF VACCINE-PREVENTABLE CHILDHOOD INFECTIOUS DISEASES: A SYSTEMATIC LITERATURE REVIEW

VALUE IN HEALTH

IF6

2018-10-010

OAAI

Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review

VALUE IN HEALTH

IF6

2016-03-0119

OAAI

Assessing Patient-Reported Outcomes in Pediatric Populations With Vaccine-Preventable Infectious Diseases: A Systematic Review of the Literature (the PROCHID Study)

VALUE IN HEALTH

IF6

2016-01-013

OAAI

Penile cancer treatment costs in England

BMC PUBLIC HEALTH

IF3.6

2015-12-297

OAAI

Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis

欧洲人群头颈癌中人乳头瘤病毒患病率的meta分析

IF3.4

2014-12-1770

OAAI

THE ECONOMIC VALUE OF VACCINATION: WHY PREVENTION IS WEALTH

VALUE IN HEALTH

IF6

2014-11-0116

OAAI

TRENDS IN SECONDARY CARE COSTS FOR TREATMENT OF HEAD AND NECK CANCER IN ENGLAND

VALUE IN HEALTH

IF6

2014-11-010

OAAI

The cost of anal cancer in England: retrospective hospital data analysis and Markov model

BMC PUBLIC HEALTH

IF3.6

2014-10-315

OAAI

Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study

BMC INFECTIOUS DISEASES

IF3

2014-07-2049

OAAI

Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2014-06-1144

OAAI